Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Xenon Pharmaceuticals Inc. (NASDAQ: XENE).

Full DD Report for XENE

You must become a subscriber to view this report.


Recent News from (NASDAQ: XENE)

Is Xenon Pharmaceuticals A Stock To Consider?
Xenon Pharmaceuticals ( XENE ) made an announcement on Thursday, September 6, 2018, that it had expanded its product portfolio with a new asset. Interestingly, due to previous data associated with the asset's active ingredient, Xenon may only be required to do a single clinical study before ...
Source: SeekingAlpha
Date: September, 07 2018 18:44
Midday Gainers / Losers (09/07/2018)
Gainers:  OKTA +20% . NVUS +17% . XENE +16% . NX +16% . DRNA +15% . ZEAL +15% . SHLO +15% . TIS +13% . FIVE +13% . MCFT +11% . More news on: Okta, Inc., Novus Therapeutics, Xenon Pharmaceuticals, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 07 2018 12:47
Xenon Pharma up 15% on new pipeline candidate
Thinly traded micro cap Xenon Pharmaceuticals ( XENE +14.8% ) is up 35% higher volume, albeit on turnover of only 361K shares. More news on: Xenon Pharmaceuticals, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: September, 07 2018 12:12
Xenon expands ion channel neurology pipeline with addition of XEN496 for the treatment of epilepsy
Xenon Pharmaceuticals (NASDAQ: XENE ) expands its ion channel product pipeline with XEN496 (active ingredient ezogabine), a Kv7 potassium channel modulator for the treatment of epilepsy. More news on: Xenon Pharmaceuticals, GlaxoSmithKline, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: September, 06 2018 07:09
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a "Phase 3 Ready" Potassium Channel Modulator for the Treatment of Epilepsy
Single, Pivotal Phase 3 Clinical Trial in Approximately 20 KCNQ2-EE Patients Expected to be  Initiated in Mid-2019 Conference Call Today at 8:00 am ET Xenon to Webcast Update on Epilepsy Pipeline from Biocentury NewsMakers Conference on September 7, 2018 BURNABY, B...
Source: GlobeNewswire
Date: September, 06 2018 06:30
Xenon Pharmaceuticals (XENE) Provides Financial Support For The Study Of The New Antiepileptic Drug XEN1101 - Slideshow
The following slide deck was published by Xenon Pharmaceuticals in conjunction with this Read more ...
Source: SeekingAlpha
Date: August, 29 2018 13:34
Xenon announces positive XEN1101 pharmacodynamic data from phase 1b TMS study
Xenon Pharmaceuticals (NASDAQ: XENE ) announces positive data from its XEN1101 Phase 1b transcranial magnetic stimulation (TMS) study. XEN1101 is a Kv7 potassium channel opener being developed by Xenon for the treatment of epilepsy. The results are being presented today at the European Con...
Source: SeekingAlpha
Date: August, 29 2018 07:00
Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study
XEN1101 Demonstrates Statistically Significant Reduction in Corticospinal and Cortical Excitability as Measured by TMS-EMG and TMS-EEG XEN1101 Demonstrates Greater Effect on TMS-EMG Resting Motor Threshold at Significantly Lower Dose When Compared to Historical Ezogabine Data ...
Source: GlobeNewswire
Date: August, 29 2018 06:05
Xenon Pharmaceuticals, Inc. (XENE) CEO Dr. Simon Pimstone on Q2 2018 Results - Earnings Call Transcript
Xenon Pharmaceuticals, Inc. (XENE) Q2 2018 Results Earnings Conference Call August 07, 2018 04:30 PM ET Executives Jodi Regts - VP, Corporate Affairs & IR Dr. Simon Pimstone - CEO Ian Mortimer - President and CFO Analysts Stephen Willey - Stifel Presentation Oper...
Source: SeekingAlpha
Date: August, 11 2018 13:26
Xenon Pharma beats by $0.04
Xenon Pharma (NASDAQ: XENE ): Q2 EPS of -$0.45 beats by $0.04 . More news on: Xenon Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 07 2018 16:32

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0813.1514.2515.92212.70643,071
2018-05-176.406.456.556.35259,409
2017-03-108.408.258.408.2026,387
2017-03-098.108.408.457.8707111,828
2017-03-088.408.358.558.3087,809

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1211,77424,91947.2491Short
2018-12-1110,82531,40334.4712Cover
2018-12-108,77618,11548.4460Short
2018-12-0713,85127,95749.5439Short
2018-12-0619,55246,60841.9499Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on XENE.


About Xenon Pharmaceuticals Inc. (NASDAQ: XENE)

Logo for Xenon Pharmaceuticals Inc. (NASDAQ: XENE)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $105,314,619 - 05/11/2018
  • Issue and Outstanding: 18,002,499 - 03/02/2018

 


Recent Filings from (NASDAQ: XENE)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 18 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018

 

 


Daily Technical Chart for (NASDAQ: XENE)

Daily Technical Chart for (NASDAQ: XENE)


Stay tuned for daily updates and more on (NASDAQ: XENE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: XENE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in XENE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of XENE and does not buy, sell, or trade any shares of XENE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/